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Department of Biophysics, Medical College of Wisconsin, Milwaukee, WisconsinABSTRACT ExoU is a 74-kDa, water-soluble toxin injected directly into mammalian cells through the type III secretion system
of the opportunistic pathogen, Pseudomonas aeruginosa. Previous studies have shown that ExoU is a Ca2þ-independent phos-
pholipase that requires a eukaryotic protein cofactor. One protein capable of activating ExoU and serving as a required cofactor
was identified by biochemical and proteomic methods as superoxide dismutase (SOD1). In these studies, we carried out site-
directed spin-labeling electron paramagnetic resonance spectroscopy to examine the effects of SOD1 and substrate liposomes
on the structure and dynamics of ExoU. Local conformational changes within the catalytic site were observed in the presence of
substrate liposomes, and were enhanced by the addition of SOD1 in a concentration-dependent manner. Conformational
changes in the C-terminal domain of ExoU were observed upon addition of cofactor, even in the absence of liposomes. Double
electron-electron resonance experiments indicated that ExoU samples multiple conformations in the resting state. In contrast,
addition of SOD1 induced ExoU to adopt a single, well-defined conformation. These studies provide, to our knowledge, the first
direct evidence for cofactor- and membrane-induced conformational changes in the mechanism of activation of ExoU.INTRODUCTIONExoU is a 74-kDa, water-soluble toxin expressed by the
opportunistic pathogen Pseudomonas aeruginosa. P. aeru-
ginosa is one of the leading causes of hospital-acquired
infections (1–3), and persists chronically in individuals
who suffer from cystic fibrosis, resulting in irreversible
lung damage and mortality (4,5). The severity of these
infections is related to the bacterium’s ability to intoxicate
epithelial cells with effector proteins that are directly trans-
located into the host cell cytosol using its type III secretion
system (T3SS), a specialized injection system that bypasses
receptor-mediated uptake and prevents exposure of the
toxin to the extracellular milieu (6,7). ExoU is the most
cytotoxic of these effector proteins, and clinical strains
that secrete ExoU exhibit enhanced virulence and are
directly associated with poor clinical outcomes in suscep-
tible patients (3,8–12).
We and others have previously shown that ExoU is
a Caþ2-independent phospholipase, with broad specificity
against a wide range of phospholipid substrates (13–15).
Although toxic during transfection/infection studies in
both yeast and mammalian cells, the phospholipase activity
of ExoU was initially not detectable in reactions using
purified recombinant ExoU (rExoU) and liposome
substrates. However, rExoU activity was detectable whenSubmitted October 22, 2010, and accepted for publication January 25,
2011.
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0006-3495/11/03/1335/9 $2.00the reaction was supplemented with yeast or mammalian
cellular extracts (13). Further, protease treatment or heating
of extracts reduced their capacity to activate rExoU (13,14),
suggesting the presence of a protein cofactor. Other P. aer-
uginosa type III effectors also require a eukaryotic protein
cofactor for activity (reviewed in Hauser (16)). Biochemical
enrichments of yeast cytosolic fractions and in vitro activity
studies led to the identification of Cu/Zn superoxide dismu-
tase 1 (SOD1) as an activator of ExoU (17). Interestingly,
neither bacterial SODs nor low-molecular-weight SOD-
mimetics activate ExoU, and treatments that eliminate the
superoxide dismutase activity of SOD1 (e.g., removal of
metal ions) do not alter its ability to activate ExoU (17),
indicating that the ability of SOD1 to act as a cofactor for
ExoU is apparently unrelated to its enzymatic activity.
Thus, the details of how SOD1 activates ExoU remain
unknown.
Although little is currently known regarding the struc-
tural organization of ExoU, an N-terminal region encom-
passing residues 107–357 has been identified as the
putative catalytic domain (13,18). Limited sequence
homology with the plant patatins and human cytosolic
phospholipases enabled the identification of serine 142
(S142) and aspartate 344 (D344) as catalytic residues, and
alanine substitutions at either of these residues eliminated
ExoU phospholipase activity, confirming their role in
formation of the canonical phospholipase catalytic dyad
(13,14). In contrast, the C-terminal half of ExoU (residues
351–687) extends beyond the region of homology with
other phospholipases and has little similarity to other
protein sequences within global databases. Nonetheless,
the C-terminal domain of ExoU is essential for function.doi: 10.1016/j.bpj.2011.01.056
1336 Benson et al.Truncation of more than nine amino acid residues from the
C-terminus of ExoU dramatically abrogates activity (19),
and linker-insertion mutagenesis studies and single
amino-acid substitutions also indicate an essential role for
the C-terminal domain of ExoU (20–23).
Additionally, suppressor mutation analysis in Saccharo-
myces cerevisiae identified residues 635–643 as a required
motif for ExoU cytotoxicity (13). The above studies have
led us to a model in which ExoU contains a relatively
well-defined N-terminal catalytic domain and a C-terminal
domain of unknown structure. The exact functional role of
the C-terminal domain is also uncertain, but may involve
mediating the interaction of ExoU with its obligatory
cofactor and/or the target membrane. It is also unclear
whether the cofactor acts to convert ExoU to an active
conformation, recruits ExoU to its target membrane, or
plays a role in both processes. To begin to address these
questions, goals of this study were to determine whether
interaction with cofactor and/or target liposomes produced
conformational changes in either the C-terminal domain
or active site region of ExoU.
To test the hypothesis that SOD1 alters the conformation
of ExoU to an active state, we have carried out studies
utilizing site-directed spin-labeling (SDSL) electron para-
magnetic resonance (EPR) spectroscopy. SDSL is a power-
ful method for examining protein structure and dynamics
that is not limited by a protein’s size or the complexity of
its environment (24–27). The SDSL technique involves
modifying selectively introduced cysteine residues with
a nitroxide spin label (Fig. 1), which gives rise to EPR
spectra that are highly sensitive to local conformational
dynamics. In addition, when two spin labels are introduced
into a protein, double electron-electron resonance (DEER)
methods can be used to determine the distance between
the two nitroxides over a range of ~20–60 A˚ (28,29),
providing a complementary approach for investigating
changes in protein structure (30–34). For our initial SDSL
studies on ExoU, spin labels were introduced at sites near
the catalytic residue S142 and within the functionally
important E635–S643 motif. Both continuous-wave (cw)
EPR and DEER studies demonstrate that interaction with
SOD1 produces conformational changes near the active
site as well as in the C-terminal domain of ExoU. These
studies also indicate that ExoU is conformationally flexible
in the absence of SOD1, adopting a well-defined structure
only in the presence of the cofactor. To our knowledge,FIGURE 1 The MTSL spin label (left) reacts with the cysteine sulfhydryl
group to yield the R1 side chain (right).
Biophysical Journal 100(5) 1335–1343this is the first direct demonstration of a cofactor-induced
conformational change in ExoU.MATERIALS AND METHODS
Reagents
Bovine Cu/Zn SOD1, Sephacryl S-200 HR resin (GE Healthcare, Piscat-
away, NJ), monosodium L-glutamic acid, and MES ((n-morpholino)etha-
nesulfonic acid) were purchased from Sigma Aldrich (St. Louis, MO).
Talon cobalt affinity chromatography resin was obtained from Clontech
(Mountain View, CA). PED6 (N-((6-(2,4-dinitrophenyl)amino)hexanoyl)-
2-(4,4-difluoro-5,7-dimethyl-4-bora-2A,3A-diaza-s-indacene-3-pentanoyl)-
1-hexadecanoyl-sn-glycero-3-phosphoethanolamine, triethylammonium
salt) was fromMolecular Probes (Carlsbad, CA). The methanethiosulfonate
spin label MTSL (1-oxyl-2,2,5,5-tetramethylpyrroline-3-methylmethane-
thiosulphonate) was purchased from Toronto Research Chemicals (North
York, ON, Canada). Benzamidine Sepharose 6B resin was from GE Health-
care. Lipids POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine)
and POPS (1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine) were
purchased from Avanti Polar Lipids (Alabaster, AL).Bacterial strains, plasmids, and growth
conditions
Escherichia coli BL21 pLysS pET15exoU and cysteine variants were
cultivated in Luria-Bertani medium containing ampicillin (100 mg/mL)
and chloramphenicol (30 mg/mL). Cysteine mutagenesis was performed
using the Change-IT site-directed mutagenesis kit according to the manu-
facturer’s protocol (USB, Cleveland, OH).Protein expression and spin-labeling
The purification of rExoU and cysteine variants was performed as previously
described (35), withmodifications to incorporate the spin label. An overnight
culture of BL21 pLysS pET15exoUwas subcultured (1:60) in Luria-Bertani
medium containing the appropriate antibiotics and grown at 37C for 2 h.
The expression of rExoU was induced with 0.25 mM Isopropyl b-D-1 thio-
galactopyranoside for 2 h at 30C. Soluble lysate was obtained by French
press breakage in the presence of DNase, RNase, and protease inhibitors
(35). After centrifugation, the cleared lysate containing histidine-tagged
rExoU was incubated with Talon cobalt affinity resin that had been equili-
brated with binding buffer (50 mM Na2HPO4, 5 mM imidazole, and
300 mM NaCl, pH 7) at 4C, washed with 10 column volumes of binding
buffer, and then eluted with a buffer containing 50 mM sodium phosphate,
300 mM NaCl, and 100 mM imidazole, pH 7.0. The eluted fraction was
passed through Benzamidine Sepharose 6B resin (Amersham Pharmacia
Biotech, Piscataway, NJ) to remove potential serine protease contaminants.
Spin labeling to convert cysteine residues to the nitroxide R1 side chain
(Fig. 1) was carried out by addition of MTSL (10-fold molar excess relative
to cysteine) and incubation overnight at 4C in elution buffer containing
a final concentration of 20% (v/v) glycerol. The N-terminal 6 histidine
tag was removed by a 2 h digestion with 50 units of thrombin at 4C,
and the digested material was passed through Benzamidine Sepharose 6B
resin (Amersham Pharmacia Biotech) to remove the thrombin. Spin-labeled
rExoU was further purified and excess MTSL removed by passing the
sample through a Sephacryl S-200 HR size exclusion column (1.6 
40 cm; GE Healthcare) equilibrated with 10 mM Tris, 15 mM NaCl, and
20% glycerol, pH 7.0. Fractions with the highest protein content were
pooled and concentrated at 4C using centrifugal spin concentrators
(30 kDa MWCOAmicon Ultra; Millipore, Billerica, MA) to a final concen-
tration of ~0.32 mM. Analysis by sodium dodecyl-sulfate polyacrylamide
gel electrophoresis indicated that the protein was >95% pure as assessed
by Coomassie-blue staining (see Fig. S1 in the Supporting Material).
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Liposomes were prepared by drying appropriate amounts of chloroform
stock solutions of POPC and POPS to give a 1:1 molar ratio under N2,
followed by further removal of the solvent under vacuum. The dried lipid
film was suspended at a concentration of 14 mM total lipid in 10 mM
Tris, 15 mM NaCl, and 20% glycerol, pH 7.0 and sonicated (five times
for 15 s each at 60% max power in a Misonix sonicator 3000; Qsonica,
Newtown, CT) to produce a clear, opalescent solution of small unilamellar
vesicles. Sonication debris was removed by centrifugation (5000  g,
10 min, 4C) in an Eppendorf microcentrifuge.ExoU activity assay
ExoU phospholipase activity was measured using an optimized in vitro
assay as recently described (35). PED6 is a nonfluorescent lipid analog
containing aBIODIPYfluorophore on the sn-2 acyl chain and adinitrophenyl
quenching moiety in the headgroup. Hydrolysis of PED6 results in de-
quenching of the highly fluorescent BIODIPY group, producing an increase
in fluorescence that is proportional to the amount of substrate cleaved.
Relative phospholipase activity of a given ExoU mutant is compared to
wild-type (wt) ExoU based on the maximum rate of PED6 hydrolysis.
Briefly, between 100 and 400 ng ExoU was mixed in a 96-well microtiter
plate with (final concentrations) 30 mM PED6, 750 mMmonosodium gluta-
mate, 50 mM MES pH 6.3, and 10 mg bovine liver SOD1 in a final volume
of 50 mL. Blank wells contained all components except SOD1. The reaction
was initiated by addition of ExoU and fluorescence was read at 15 min
intervals for 6 h (excitation 488 nm, emission 511 nm) on a SpectraMax
M2 plate reader (Molecular Dynamics, Mountain View, CA). Recombinant
wt ExoU was included in each assay as a positive control. Aliquots of
recombinant wt ExoU were stored at 80C, and gave consistent rates of
PED6 hydrolysis over several months.TABLE 1 Phospholipase activity of rExoU cysteine mutants
before and after spin labeling
Sample free Cys þ MTSL
I135C NA* NA*
S137C 635 3 51 5 2
S139C 565 9 7 5 1
S141C 455 4 NA*
A641C 355 7 19 5 4
T642C 925 6 95 5 3
S643C 1035 8 98 5 5
Phospholipase activities are % (mean 5 SE) of recombinant wild-type
ExoU.
*NA ¼ No activity.Electron paramagnetic resonance spectroscopy
Continuous wave (cw) EPR spectroscopy was carried out at room temper-
ature (23 5 1C) on an Elexsys E500 spectrometer (Bruker Biospin,
Billerica, MA) equipped with a high-Q cavity operating at X-band. Samples
(32 mL total volume contained in 50 mL glass capillaries) were prepared by
mixing spin-labeled ExoU, POPC/POPS (1:1) liposomes, and SOD1 (from
a 2 mM stock solution in 10 mM Tris, 15 mM NaCl, and 20% glycerol, pH
7.0) to give a final concentration of 80 mM ExoU and the desired final
concentrations of liposomes and/or SOD1. Spectrometer conditions were:
time constant 10.28 ms, conversion time 20.48 ms, scan time 20.97 s,
a 100 kHz field modulation amplitude of 1.0 G, 10 mW microwave power,
and a sweep width of 100 G.
Experimental spectra were fit to the MOMD model of Budil et al. (36)
using a version of the program NLSL written in LABVIEWand generously
provided by Christian Altenbach and Wayne L. Hubbell (Jules Stein Eye
Institute, University of California, Los Angeles). Values of the g and A
tensors were fixed at gxx ¼ 2.0078, gyy ¼ 2.0058, gzz ¼ 2.0022, Axx ¼
6.2 G, Ayy ¼ 5.9 G, and Azz ¼ 37 G (37,38). Angles relating the diffusion
tensor to the magnetic tensor of the nitroxide spin label (a, b, g) were
assigned values of (0, 36, 0) as previously described for the R1 side chain
attached to the soluble protein, T4 lysozyme (37).
Spectra were fit by varying the restoring potential coefficient c20 and
rotational diffusion tensor parameters (Rx, Ry, Rz), initially assuming axial
symmetry (Rx¼ Ry) and with particular emphasis on fitting the outer hyper-
fine extrema. Rotational correlation times (tc ¼ 1/6 [10hRi], where hRi ¼
[(Rx)(Ry)(Rz)]1/3) and order parameters (S) were calculated as previously
described (37).
Four-pulse double electron-electron resonance (DEER) spectroscopy
(28) was carried out at ~9.5 GHz on an E580 spectrometer (Bruker Biospin)
equipped with a 3-mm split-ring resonator. Samples (24 mL total volume)
containing double-labeled ExoU (~200 mM) with or without SOD and/orliposomes and a final concentration of 25% (v/v) perdeuterated glycerol
(Sigma Aldrich) as cryoprotectant were placed in 2  2.4 mm glass capil-
laries and flash-frozen by immersion into liquid N2. Sample temperature
during the experiment was maintained at 80 K using an Oxford cryostat.
Observer pulses were positioned at the low field maximum with p and
p/2 pulse lengths of 32 ns and 16 ns, respectively. Pump pulses were posi-
tioned at the center field maximum. Data were corrected for background
decay assuming a homogeneous three-dimensional protein distribution
and analyzed by model free Tikhonov regularization using DeerAnaly-
sis2010 software (http://www.epr.ethz.ch/) (39). DEER acquisition times
ranged between 8 and 16 h.RESULTS
To initiate our SDSL studies of rExoU we created seven
single-cysteine variants (wild-type ExoU contains no native
cysteines), including four near the catalytic serine residue
S142 (I135C, S137C, S139C, and S141C) and three
(A641C, T642C, and S643C)within a functionally important
motif (residues 635–643) previously identified in the
C-terminal domain.Analysis of SOD1-stimulated phospholi-
pase activity indicated that I135C was catalytically inactive.
S137C, S139C, and S141C retained between 45 and 63% of
wild-type activity in the free thiol state, consistent with the
relatively conservative Ser to Cys mutation (Table 1).
Upon spin labeling, the phospholipase activities of
S139R1 and S141R1 were substantially reduced; however,
S137R1 retained ~50% of wt activity (Table 1). Cysteine
mutagenesis was reasonably well tolerated for A641C
(35% wt activity, 19% after spin labeling), and cysteine
substitution at T642 and S643 had essentially no effect on
the phospholipase activity of rExoU. T642R1 and S643R1
also retained full activity after spin labeling. These results
are consistent with a wide range of studies showing that
site-specific cysteine mutagenesis is generally well tolerated
(e.g., 27,33,40–44), and indicate that the majority of these
sites are well suited for further study by SDSL.Conformational changes in close proximity
to the active site
EPR spectra of the spin-labeled rExoU single-cysteine vari-
ants located near the catalytic S142 residue are shown in
Fig. 2. Each of these sites shows the presence of a populationBiophysical Journal 100(5) 1335–1343
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FIGURE 2 EPR spectra of MTSL-labeled cysteine variants near catalytic
residue S142 of ExoU. (Solid lines) Experimental spectra. (Shaded lines)
Two-component simulations. Spectra are scaled to approximately equal
amplitude of the center line.
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FIGURE 3 Liposome and SOD1-induced conformational changes in
S137R1. Samples contained ExoU-S137R1 in 10 mM Tris pH 7.0,
15 mM NaCl, and 20% glycerol. (A) Buffer control; (B) after addition of
POPC/POPS (1:1) liposomes; and (C–E) after addition of liposomes and
SOD1. The SOD1:ExoU molar ratios were (C) 6.25:1, (D) 12.5:1, and
(E) 25:1. The lipid/ExoU molar ratio was held constant at 44:1. Spectra
are scaled to equal amplitude of the center line. Positions of the more immo-
bile (i) and mobile (m) motional states of the nitroxide side chain are indi-
cated. Overlays of spectra A and B and of spectra A and E are provided in
Fig. S4.
1338 Benson et al.of spin labels that is relatively immobilized, with outer
hyperfine splittings in the range of 65–69 G and rotational
correlation times of ~10–20 ns (see Fig. S3 and Table S1),
indicating the presence of extensive tertiary contacts that
limit the mobility of the R1 side chain. Sites S135R1,
S139R1, and S141R1, which retain little or no catalytic
activity after spin labeling, showed no change in their
EPR spectra upon the addition of either SOD1 or liposomes
alone, or with the combination of liposomes and SOD1 (data
not shown). In contrast, obvious spectral changes occurred
for S137R1 upon the addition of liposomes and SOD1
(Fig. 3 and Fig. S4).
As noted above, the EPR spectrum of S137R1 reflects the
presence of a least two motional components, corresponding
to relatively mobile (m) and immobile (i) states of the nitro-
xide side chain (Fig. 3, see also Fig. S3). Addition of POPC/
POPS (1:1) liposomes alone produced a very slight shift
toward increased mobility (Fig. 3 B and Fig. S4); no changes
were observed upon addition of SOD1 alone (data not
shown). However, the addition of substrate liposomes in
combination with SOD1 produced substantial changes in
the rotational mobility of S137R1 (Fig. 3, C–E, see also
Fig. S4), changing both the motional parameters and relative
populations of the mobile and immobile spin states. In the
absence of either liposomes or SOD1 (i.e., Fig. 3 A), theBiophysical Journal 100(5) 1335–1343more mobile population accounted for ~56% of the total
spin concentration, increasing to ~80% in the presence of
a 25-fold excess of SOD1 (Fig. S5). These results clearly
demonstrate the occurrence of a conformational change in
close proximity to the catalytic site of ExoU, indicating
that the S137R1 side chain experiences increased motional
freedom in the presence of SOD1 and substrate liposomes.Conformational changes in the C-terminal domain
EPR spectra of A641R1, T642R1 and S643R1, located in
the C-terminal domain of rExoU, are shown in Fig. 4.
T642C and S643C retain essentially full catalytic activity
as compared to wt rExoU, both before and after spin
labeling, while A641C retains ~35% of wt activity (19%
after labeling) (Table 1). As shown in Fig. 4, these sites
are also characterized by complex EPR spectra with rela-
tively mobile and immobile states of the spin-label side
chain. The EPR spectra of A641R1 and T642R1 were
unchanged upon the addition of liposomes (not shown),
and showed only small increases in the more mobile spin
population in the presence of SOD1 (see Fig. S6). S643R1
im
G02
FIGURE 4 EPR spectra of MTSL-labeled cysteine mutants in the
C-terminal domain of ExoU. (Solid lines) Experimental spectra. (Shaded
lines) Multicomponent simulations. (Arrows) Positions of relatively mobile
(m) and immobile (i) motional states of the R1 side chain.
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FIGURE 5 Liposome and SOD1-induced conformational changes in
S643R1. Samples contained ExoU-S643R1 in buffer, after addition of lipo-
somes, after addition of SOD1, and after addition of both liposomes and
SOD1. The lipid/ExoU and SOD1/ExoU molar ratios were 44:1 and
15:1, respectively. Positions of the more immobile (i) and mobile (m)
motional states of the nitroxide side chain are indicated.
Activation of ExoU 1339also showed no change upon the addition of liposomes alone
(Fig. 5 B). However, addition of SOD1 to S643R1 produced
a dramatic change in which the more immobile component
disappeared completely (Fig. 5 C, see also Fig. S6). The
EPR spectrum of S643R1 in the presence of both liposomes
and SOD1 (Fig. 5 D) was identical to that in the presence of
SOD1 alone. Thus, even in the absence of substrate lipo-
somes, interaction with SOD1 produces a conformational
change that alters the structure and/or dynamics in the
C-terminal domain of ExoU.
Two-component EPR spectra such as those observed
for A641R1, T642R1, and S643R1 can arise from either
different conformational states of the protein, or from
different rotameric states of the nitroxide side chain relative
to the protein backbone. To distinguish between these alter-
natives for S643R1, we examined the effects of sucrose on
the relative populations of the more mobile and immobile
motional states of the spin label. It has been previously
shown that protein conformational states are sensitive to
the presence of osmolytes in the surrounding medium,
with higher osmolyte concentrations favoring more-
compact structures that typically correspond to the more-
immobilized state of the spin label (45–47). In contrast,
studies in several well-defined model systems have indi-
cated that equilibria between different rotameric states of
the R1 side chain are generally not sensitive to osmolytes
(47). The effect of increasing sucrose concentrations onthe EPR spectrum of S643R1 is shown in Fig. 6. As can
be seen, the addition of sucrose caused a pronounced
increase in the relative population of the more immobilized
state of the R1 side chain, from 42% in the control sample to
54% in the presence of 45% (w/v) sucrose. This result
suggests that the complexity observed in the EPR spectra
of S643R1 arises due to the presence of distinct conforma-
tional states in the C-terminal domain.DEER analysis of SOD1-induced conformational
changes
To further characterize SOD1-induced conformational
changes in ExoU, we used DEER spectroscopy to measure
the distance between S137R1 and S643R1. In both the pres-
ence and absence of SOD1, dipole-dipole interaction
between the two spin labels gave rise to modulation of the
electron spin echo amplitude (Fig. 7). Model-free analysis
of the dipolar evolution by Tikhonov regularization indi-
cated that in the absence of SOD1 there exists a complex
distance distribution between the two sites with a primary
distance of 22 A˚ and lesser populations at 26.5 A˚, 30.4 A˚,
and 38 A˚. Given that the DEER echo curve for the control
extended only to 1.2 ms, the peak observed at 38 A˚ is some-
what questionable. However, the dipolar evolution curve
was poorly-fit if this distance was suppressed during the
analysis (see Fig. S9). Thus, the peak at 38 A˚ appears to
represent a population of spins with a separation distance
of 38 A˚ or greater.Biophysical Journal 100(5) 1335–1343
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FIGURE 6 Effect of sucrose on S643R1. Comparison of the EPR spectra
of S643R1 in buffer alone and in the presence of various concentrations
(w/v) of sucrose. Spectra were normalized to the same integrated intensity.
1340 Benson et al.In marked contrast, upon addition of SOD1 the distance
distribution was dominated by a single distance at 31 A˚
(Fig. 7). In this case, suppression of the two minor peaks
caused only a slight change in the quality of the fits (see
Fig. S10), so that the presence of conformations correspond-
ing to these distances must be considered questionable.
These peaks may arise from small populations of ExoU
that retain native conformations (i.e., with nitroxide-nitro-
xide distances of 22 A˚ and >38 A˚, as observed in the
absence of SOD1), or may arise due to artifacts of the Ti-
khonov regularization analysis. Nonetheless, the substantial
alterations in the dipolar evolution curves and their associ-
ated distance distributions seen in Fig. 7 clearly indicate
the occurrence of a SOD1-induced conformational change
in ExoU. Further, these results suggest that ExoU samplesA
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Biophysical Journal 100(5) 1335–1343multiple conformational states in the resting state, and
adopts a single predominant conformation only upon inter-
action with its cofactor.DISCUSSION
ExoU, a potent phospholipase toxin produced by P. aerugi-
nosa and injected into target cells through the type III
secretion system, requires interaction with a eukaryotic
cofactor for activity (13,14). The requirement of a eukary-
otic activator provides an important safeguard for the bacte-
rium, as ExoU is fully capable of hydrolyzing bacterial
membrane lipids (15). We and others have previously shown
that Cu/Zn SOD1 isolated from eukaryotic sources activates
ExoU in vitro (17,22,23,35), by an unknown mechanism
that is independent of SOD1 enzymatic activity (17). We
have suggested that the ability of SOD1 to activate ExoU
involves protein-protein interactions that induce a conforma-
tional change in ExoU. To our knowledge, these studies
provide the first direct demonstration of conformational
changes in ExoU upon the addition of SOD1 and/or
substrate liposomes.
Conformational changes were observed both near the
catalytic active site and at sites located in the C-terminal
domain of ExoU. For S137R1, located in close proximity
to catalytic residue S142, a slight increase in rotational
mobility was observed in the presence of liposomes alone,
suggesting that the structure of the catalytic site is sensitive
to the presence of a target membrane. This increase in
mobility became much more pronounced upon addition of
SOD1 and liposomes in combination, and exhibited
a concentration dependence on the amount of added
SOD1, demonstrating the occurrence of SOD1/liposome-
induced structural changes within the ExoU catalytic site.
We also observed SOD1-induced conformational changes
in the C-terminal domain of ExoU, at sites A641, T642, andB
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FIGURE 7 DEER evidence for a SOD1-induced
conformational change in ExoU. (A and C) Dipolar
evolution curves (black) and fits (red) obtained
using model-free Tikhonov regularization for the
S137R1-S643R1 rExoU double cysteine variant
in the (A) absence and (C) presence of SOD1.
(B and D) Corresponding distance distributions in
the (B) absence and (D) presence of SOD1. The
regularization parameter (a) was 10 for both fits.
L-curves are given in Fig. S8.
FIGURE 8 Model for the interaction of ExoU (gray) with its activating
cofactor (blue) and the membrane bilayer. The observation of multiple
distances between S643R1 and S137R1 suggests that the C-terminal
domain may be conformationally flexible in the absence of the cofactor.
SOD1 is envisioned as causing a realignment of the N- and C-terminal
domains that facilitates membrane binding and exposure of the catalytic
site to its lipid substrate. The conformational change in S137R1 observed
in the presence of liposomes and SOD1 is represented as a change in the
shape of the active site.
Activation of ExoU 1341S643. These sites are located in a region of the protein previ-
ously identified as being important for ExoU cytotoxicity
(13), despite being distal from the active site. In contrast
to the effects observed with S137R1, addition of SOD1
alone was able to induce changes in the rotational mobility
of a spin-label side chain introduced at these sites, without
the requirement for substrate liposomes. For each of these
sites, the cw EPR spectrum indicates the presence of at least
two conformational states and interaction with SOD1
altered the relative populations of these states. In the case
of S643R1, interaction with SOD1 completely eliminated
the more restricted (immobile) conformation.
DEER results also indicate that ExoU samples multiple
conformations in the absence of cofactor. For the S137R1-
S643R1 pair, analysis of the dipolar evolution by Tikhonov
regularization indicated multiple distinct distances, ranging
from 22 A˚ to 38 A˚with the most prominent peak at an inter-
spin distance of 22.4 (51.2) A˚. In sharp contrast, after addi-
tion of SOD1 to the 137–643 pair we observed a single
predominant peak in the DEER distance distribution, with
an interspin distance of 30.6 (52.0) A˚. These results
provide strong evidence that interaction of ExoU with its
protein cofactor alone is sufficient to generate a substantial
conformational change in ExoU.
A schematic, working model representing our current
understanding of cofactor-induced conformational changes
and membrane interactions for ExoU is shown in Fig. 8.
In the unliganded state, ExoU exhibits conformational flex-
ibility resulting in the observation of multiple distances
between S137 (near or within the active site) and S643 in
the C-terminal domain (Fig. 8 A). Similarly, several of the
spin-labeling sites examined in this study, including all three
in the C-terminal domain, exhibited cw EPR spectra in the
resting state indicative of conformational heterogeneity.
This is indicated in Fig. 8, A and B, as multiple orientations
of the C-terminal domain, although the exact nature of
conformational heterogeneity in the absence of cofactor
(i.e., structural flexibility within either or both domains,
heterogeneity in the spatial relationship between domains)
is currently unknown. ExoU is apparently capable of some
degree of interaction with the target membrane in the
absence of cofactor, as indicated by our observation of
changes in the local environment surrounding S137 upon
addition of liposomes (Fig. 8 B). However, in the absence
of cofactor this interaction does not result in productive
phospholipase activity, either because the active site confor-
mation is not fully formed, is not accessible to substrate, or
because the phospholipid substrate cannot be properly
engaged. Such a catalytically inactive state would preclude
degradation of the bacterial cell membrane before export,
serving as an important mechanism of protection for the
bacterium from its own toxin.
Our data suggests that, upon interaction with a eukaryotic
cofactor, a catalytically active conformation of ExoU is
selected or stabilized, with a single, well-defined distancebetween S137 and S643, even in the absence of liposomes
(Fig. 8 C). Finally, membrane association of ExoU in the
presence of the activating cofactor results in full catalytic
activity, with evident conformational changes in the active
site that are dependent on the presence of the cofactor
(Fig. 8 D). In Fig. 8 D, we also indicate an interaction
between the C-terminal domain and the target membrane, re-
flecting several studies that have implicated the C-terminal
domain in membrane localization (e.g., (20–22)). Thus, we
propose that the co-factor-induced conformational change
in ExoU serves two functions in the activation mechanism:
facilitating membrane association and establishing an
open, catalytically competent conformation at the active site.
In our estimation, this study provides the first direct struc-
tural evidence showing that interaction of ExoU with an
activating cofactor results in conformational changes in
both its C-terminal domain and in close proximity to its
active site. By understanding the detailed mechanism of
the cofactor-mediated activation of ExoU, specific therapies
that target this mechanism may be developed to reduce or
prevent tissue damage due to this potent virulence factor.
Additional studies to further define the structural arrange-
ment of the C-terminal domain with respect to the active
site are in progress.SUPPORTING MATERIAL
Ten figures and two tables are available at http://www.biophysj.org/
biophysj/supplemental/S0006-3495(11)00141-X.Biophysical Journal 100(5) 1335–1343
1342 Benson et al.We thank Dr. Candice Klug for critical reading of the manuscript.
This work was supported in part by National Institutes of Health grant No.
AI49577 (to D.W.F.). The National Biomedical EPR Center is supported by
National Institutes of Health grant No. EB001980.REFERENCES
1. Armour, A. D., H. A. Shankowsky,., E. E. Tredget. 2007. The impact
of nosocomially-acquired resistant Pseudomonas aeruginosa infection
in a burn unit. J. Trauma. 63:164–171.
2. Wisplinghoff, H., T. Bischoff, ., M. B. Edmond. 2004. Nosocomial
bloodstream infections in US hospitals: analysis of 24,179 cases
from a prospective nationwide surveillance study. Clin. Infect. Dis.
39:309–317.
3. Hauser, A. R., E. Cobb, ., J. Rello. 2002. Type III protein secretion
is associated with poor clinical outcomes in patients with ventilator-
associated pneumonia caused by Pseudomonas aeruginosa. Crit.
Care Med. 30:521–528.
4. Lyczak, J. B., C. L. Cannon, and G. B. Pier. 2002. Lung infections
associated with cystic fibrosis. Clin. Microbiol. Rev. 15:194–222.
5. Pier, G. B. 2002. CFTR mutations and host susceptibility to Pseudo-
monas aeruginosa lung infection. Curr. Opin. Microbiol. 5:81–86.
6. Galan, J. E., and A. Collmer. 1999. Type III secretion machines:
bacterial devices for protein delivery into host cells. Science.
284:1322–1328.
7. Galan, J. E., and H. Wolf-Watz. 2006. Protein delivery into eukaryotic
cells by type III secretion machines. Nature. 444:567–573.
8. Finck-Barbancon, V., J. Goranson, ., D. W. Frank. 1997. ExoU
expression by Pseudomonas aeruginosa correlates with acute cytotox-
icity and epithelial injury. Mol. Microbiol. 25:547–557.
9. Roy-Burman, A., R. H. Savel,., J. P. Wiener-Kronish. 2001. Type III
protein secretion is associated with death in lower respiratory and
systemic Pseudomonas aeruginosa infections. J. Infect. Dis.
183:1767–1774.
10. Holder, I. A., A. N. Neely, and D. W. Frank. 2001. Type III secretion/
intoxication system important in virulence of Pseudomonas aeruginosa
infections in burns. Burns. 27:129–130.
11. Holder, I. A., A. N. Neely, and D. W. Frank. 2001. PcrV immunization
enhances survival of burned Pseudomonas aeruginosa-infected mice.
Infect. Immun. 69:5908–5910.
12. Scheetz, M. H., M. Hoffman, ., A. R. Hauser. 2009. Morbidity
associated with Pseudomonas aeruginosa bloodstream infections.
Diagn. Microbiol. Infect. Dis. 64:311–319.
13. Sato, H., D. W. Frank,., T. Sawa. 2003. The mechanism of action of
the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU.
EMBO J. 22:2959–2969.
14. Phillips, R. M., D. A. Six, ., P. Ghosh. 2003. In vivo phospholipase
activity of the Pseudomonas aeruginosa cytotoxin ExoU and protec-
tion of mammalian cells with phospholipase A2 inhibitors. J. Biol.
Chem. 278:41326–41332.
15. Sato, H., J. B. Feix,., D. W. Frank. 2005. Characterization of phos-
pholipase activity of the Pseudomonas aeruginosa type III cytotoxin,
ExoU. J. Bacteriol. 187:1192–1195.
16. Hauser, A. R. 2009. The type III secretion system of Pseudomonas
aeruginosa: infection by injection. Nat. Rev. Microbiol. 7:654–665.
17. Sato, H., J. B. Feix, and D. W. Frank. 2006. Identification of superoxide
dismutase as a cofactor for the Pseudomonas type III toxin, ExoU.
Biochemistry. 45:10368–10375.
18. Finck-Barbancon, V., and D. W. Frank. 2001. Multiple domains are
required for the toxic activity of Pseudomonas aeruginosa ExoU.
J. Bacteriol. 183:4330–4344.
19. Stirling, F. R., A. Cuzick, ., T. J. Evans. 2006. Eukaryotic localiza-
tion, activation and ubiquitinylation of a bacterial type III secreted
toxin. Cell Microbiol. 8:1294–1309.Biophysical Journal 100(5) 1335–134320. Rabin, S. D., and A. R. Hauser. 2005. Functional regions of the
Pseudomonas aeruginosa cytotoxin ExoU. Infect. Immun. 73:
573–582.
21. Rabin, S. D., J. L. Veesenmeyer,., A. R. Hauser. 2006. A C-terminal
domain targets the Pseudomonas aeruginosa cytotoxin ExoU to the
plasma membrane of host cells. Infect. Immun. 74:2552–2561.
22. Veesenmeyer, J. L., H. Howel, ., A. R. Hauser. 2010. Role of the
membrane localization domain of the Pseudomonas aeruginosa
effector protein ExoU in cytotoxicity. Infect. Immun. 78:3346–3357.
23. Schmalzer, K. M., M. A. Benson, and D. W. Frank. 2010. Activation of
ExoU phospholipase activity requires specific C-terminal regions.
J. Bacteriol. 192:1801–1812.
24. Hubbell, W. L., D. S. Cafiso, and C. Altenbach. 2000. Identifying
conformational changes with site-directed spin labeling. Nat. Struct.
Biol. 7:735–739.
25. Columbus, L., and W. L. Hubbell. 2002. A new spin on protein
dynamics. Trends Biochem. Sci. 27:288–295.
26. Fanucci, G. E., and D. S. Cafiso. 2006. Recent advances and applica-
tions of site-directed spin labeling. Curr. Opin. Struct. Biol. 16:
644–653.
27. Klug, C. S., and J. B. Feix. 2008. Methods and applications of site-
directed spin labeling EPR spectroscopy. Methods Cell Biol. 84:
617–658.
28. Pannier, M., S. Veit,., H. W. Spiess. 2000. Dead-time free measure-
ment of dipole-dipole interactions between electron spins. J. Magn.
Reson. 142:331–340.
29. Borbat, P. P., and J. H. Freed. 2007. Measuring distances by pulsed
dipolar ESR spectroscopy: spin-labeled histidine kinases. Methods
Enzymol. 423:52–116.
30. Xu, Q., J. F. Ellena, ., D. S. Cafiso. 2006. Substrate-dependent
unfolding of the energy coupling motif of a membrane transport protein
determined by double electron-electron resonance. Biochemistry.
45:10847–10854.
31. Zhou, Z., S. C. DeSensi, ., A. H. Beth. 2007. Structure of the
cytoplasmic domain of erythrocyte band 3 hereditary spherocytosis
variant P327R: band 3 Tuscaloosa. Biochemistry. 46:10248–10257.
32. Altenbach, C., A. K. Kusnetzow, ., W. L. Hubbell. 2008.
High-resolution distance mapping in rhodopsin reveals the pattern of
helix movement due to activation. Proc. Natl. Acad. Sci. USA.
105:7439–7444.
33. Zou, P., M. Bortolus, and H. S. Mchaourab. 2009. Conformational
cycle of the ABC transporter MsbA in liposomes: detailed analysis
using double electron-electron resonance spectroscopy. J. Mol. Biol.
393:586–597.
34. Blackburn, M. E., A. M. Veloro, and G. E. Fanucci. 2009.
Monitoring inhibitor-induced conformational population shifts in
HIV-1 protease by pulsed EPR spectroscopy. Biochemistry. 48:8765–
8767.
35. Benson, M. A., K. M. Schmalzer, and D. W. Frank. 2010. A sensitive
fluorescence-based assay for the detection of ExoU-mediated PLA2
activity. Clin. Chim. Acta. 411:190–197.
36. Budil, D. E., S. Lee, ., J. H. Freed. 1996. Nonlinear-least-squares
analysis of slow motion EPR spectra in one and two dimensions using
a modified Levenberg-Marquardt algorithm. J. Magn. Res. A. 120:
155–189.
37. Columbus, L., T. Ka´lai,., W. L. Hubbell. 2001. Molecular motion of
spin labeled side chains in a-helices: analysis by variation of side chain
structure. Biochemistry. 40:3828–3846.
38. Kusnetzow, A. K., C. Altenbach, and W. L. Hubbell. 2006. Conforma-
tional states and dynamics of rhodopsin in micelles and bilayers.
Biochemistry. 45:5538–5550.
39. Jeschke, G., V. Chechik, ., H. Jung. 2006. DEER Analysis 2006—
a comprehensive software package for analyzing pulsed ELDOR
data. Appl. Magn. Res. 30:473–498.
Activation of ExoU 134340. Altenbach, C., S. L. Flitsch,., W. L. Hubbell. 1989. Structural studies
on transmembrane proteins. 2. Spin labeling of bacteriorhodopsin
mutants at unique cysteines. Biochemistry. 28:7806–7812.
41. Isas, J. M., R. Langen,., W. L. Hubbell. 2002. Structure and dynamics
of a helical hairpin and loop region in annexin 12: a site-directed spin
labeling study. Biochemistry. 41:1464–1473.
42. Cuello, L. G., D. M. Cortes, and E. Perozo. 2004. Molecular architec-
ture of the KvAP voltage-dependent Kþ channel in a lipid bilayer.
Science. 306:491–495.
43. Jao, C. C., B. G. Hegde,., R. Langen. 2008. Structure of membrane-
bound a-synuclein from site-directed spin labeling and computational
refinement. Proc. Natl. Acad. Sci. USA. 105:19666–19671.44. Westfahl, K. M., J. A. Merten, ., C. S. Klug. 2008. Functionally
important ATP binding and hydrolysis sites in Escherichia coli
MsbA. Biochemistry. 47:13878–13886.
45. Fanucci, G. E., J. Y. Lee, and D. S. Cafiso. 2003. Spectroscopic
evidence that osmolytes used in crystallization buffers inhibit a confor-
mation change in a membrane protein. Biochemistry. 42:13106–13112.
46. Kim, M., Q. Xu, ., D. S. Cafiso. 2006. Solutes modify a conforma-
tional transition in a membrane transport protein. Biophys. J.
90:2922–2929.
47. Lopez, C. J., M. R. Fleissner, ., W. L. Hubbell. 2009. Osmolyte
perturbation reveals conformational equilibria in spin-labeled proteins.
Protein Sci. 18:1637–1652.Biophysical Journal 100(5) 1335–1343
